ライフサイエンスコーパス: Hodgkin disease

1 studies, in which the most common topic was Hodgkin disease).

2 ata on breast cancers after radiotherapy for Hodgkin disease.

3 reater risk of myeloma and leukemia, but not Hodgkin disease.

4 myeloma, and tacrolimus with a lower risk of Hodgkin disease.

5 n increased risk of non-Hodgkin lymphoma and Hodgkin disease.

6 odeficiency (SCID) mouse xenograft models of Hodgkin disease.

7 el treatment strategies for the treatment of Hodgkin disease.

8 n treatment with or without chemotherapy for Hodgkin disease.

9 1-positive malignancies such as EBV-positive Hodgkin disease.

10 atients with "lymphosarcomatosis" and 3 with Hodgkin disease.

11 mbined modality therapy, and with time after Hodgkin disease.

12 on-Hodgkin lymphoma and, to a lesser extent, Hodgkin disease.

13 posttransplantation setting in patients with Hodgkin disease.

14 t outcome in patients with favorable stage I Hodgkin disease.

15 sttransplant lymphoproliferative disease and Hodgkin disease.

16 the design of clinical trials for pediatric Hodgkin disease: 1) to reduce long-term organ injury; an

17 oth patients, but patient 2 died of relapsed Hodgkin disease 12 months after transplantation.

18 Among 1319 patients with clinical stage I-IV Hodgkin disease, 181 second malignancies and 18 third ma

19 transplant lymphoproliferative diseases, 18; Hodgkin disease, 2; and myelodysplastic syndrome, 2).

20 nk (0.1-1.9 cGy), and pelvic irradiation for Hodgkin disease (263-3,500 cGy).

21 of neoplastic diseases such as leukemia and Hodgkins'disease); - 3 patients with food allergy; - 1 p

22 n-Hodgkin lymphoma (77 patients, 208 scans), Hodgkin disease (41 patients, 182 scans), colorectal can

23 n-Hodgkin lymphoma (77 patients, 208 scans), Hodgkin disease (41 patients, 182 scans), colorectal can

24 his paper, we investigated the expression in Hodgkin disease (45 cases and 3 cell lines) of 5 intrace

25 lung, 5% and 15%-20%; prostate, 40% and 80%; Hodgkin disease, 50% and more than 90%; cervix, 40% and

26 ma, 4 B-cell acute lymphoblastic leukemia, 1 Hodgkin disease, 8 leiomyosarcoma, 1 hepatoblastoma, and

27 n help to predict the absence of mediastinal Hodgkin disease after treatment.

28 for design of novel pharmaceuticals to treat Hodgkin disease and immune system disorders.

29 ed LMP1 protein is expressed in EBV-positive Hodgkin disease and is a potential target for cytotoxic

30 Hodgkin disease and myeloma were recently included in th

31 : complete remission (CR) in 2 patients with Hodgkin disease and partial remission (PR) in a patient

32 arked with the clusterin antibody, including Hodgkin disease and primary cutaneous ALCL.

33 6, 55 and 39% respectively for NHL, myeloma, Hodgkin disease, and leukemia.

34 cs, risk, and prognostic factors of myeloma, Hodgkin disease, and lymphoid leukemia using the United

35 ancies including non-Hodgkin lymphoma (NHL), Hodgkin disease, and multiple myeloma.

36 le malignancies, including Burkitt lymphoma, Hodgkin disease, and nasopharyngeal carcinoma (NPC).

37 reased risk of systemic nonHodgkin lymphoma, Hodgkin disease, and primary central nervous lymphoma (P

38 ously underwent mantle radiation therapy for Hodgkin disease, breast cancers are more commonly seen w

39 may be detected in tonsils and EBV-negative Hodgkin disease but not in EBV-associated posttransplant

40 at are infused as treatment for EBV-positive Hodgkin disease but that are vulnerable to the TGF-beta

41 have been reported for NHL and suggested for Hodgkin disease, but long-term risks are as yet unknown.

42 models of anaplastic large cell lymphoma or Hodgkin disease, cAC10-vcMMAE was efficacious at doses a

43 ipts are found in other lymphomas (including Hodgkin disease cells) has led to the suggestion that tr

44 gkin-Reed-Sternberg (HRS) cells of classical Hodgkin disease (cHD), we correlated its expression with

45 The excess risk of second malignancy after Hodgkin disease continues to be increased after 15 to 20

46 ative disorders, including Burkitt lymphoma, Hodgkin disease, diffuse large B-cell lymphoma (DLBCL),

47 riety of hematologic malignancies, including Hodgkin disease (HD) and anaplastic large cell lymphoma

48 mphocytes, as well as on neoplastic cells of Hodgkin disease (HD) and anaplastic large cell lymphoma

49 bleomycin, vinblastine, and dacarbazine for Hodgkin disease (HD) and had undergone 4 consecutive (18

50 -risk non-Hodgkin lymphoma (NHL) or relapsed Hodgkin disease (HD) and NHL.

51 defines the incidence and recurrence risk of Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL) afte

52 or types, but its expression and function in Hodgkin disease (HD) are unknown.

53 We developed an infiltrating model of Hodgkin disease (HD) by injecting an adherent population

54 t Hodgkin and Reed-Sternberg (H/RS) cells of Hodgkin disease (HD) express several members of the tumo

55 er Society predicts about 7,400 new cases of Hodgkin Disease (HD) in the year 2000 in the US.

56 the non-HIV setting, patients with relapsed Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) have

57 sponse rates in patients with HIV-associated Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) treat

58 age of patients with relapsed and refractory Hodgkin disease (HD) with high-dose chemoradiotherapy (H

59 etter for those with chemosensitive disease, Hodgkin disease (HD), and low-grade non-Hodgkin lymphoma

60 ing cause of death in long-term survivors of Hodgkin disease (HD), with exceptionally high risks of b

61 ong been implicated in sporadic and familial Hodgkin disease (HD), with recent case-control studies s

62 s appear to account for much of the risk for Hodgkin disease (HD).

63 mortality was increased among patients with Hodgkin disease (HD; relative risk [RR] = 3.6), non-Hodg

64 tal Epstein-Barr virus infection, lymphomas, Hodgkins disease, immunodeficiency, aplastic anemia and

65 sitive to the treatment regimens devised for Hodgkin disease in adults, long-term toxicity is enhance

66 myelogenous leukemia and primary refractory Hodgkin disease in patients 1 and 2, respectively.

67 A retrospective study of 30 cases of Hodgkin disease in patients who underwent high-dose carm

68 ties such as peripheral T-cell lymphomas and Hodgkin disease in patients with a history of chronic in

69 The malignant Reed-Sternberg cell of Hodgkin disease is an aberrant B cell that persists in a

70 The excess risk of second malignancy after Hodgkin disease is an increasing problem.

71 Although childhood Hodgkin disease is sensitive to the treatment regimens d

72 ression and truncated in B-cell lymphoma and Hodgkin disease, is found to fuse with DEXI in 48% of no

73 Lymphocyte-predominant Hodgkin disease (LPHD) is a unique clinical entity chara

74 ing proteins between the 2 major subtypes of Hodgkin disease may be of diagnostic value.

75 NHL (n = 57), multiple myeloma (n = 24), or Hodgkin disease (n = 14) diagnosed a mean of 21 years af

76 hic PTLD (n = 1); monomorphic PTLD (n = 27), Hodgkin disease (n = 2).

77 ta, guidelines for follow-up of survivors of Hodgkin disease need to be redefined.

78 treated for primary brain cancer, leukemia, Hodgkin disease, non-Hodgkin lymphoma, kidney tumor, neu

79 2 739 patients receiving autotransplants for Hodgkin disease or non-Hodgkin lymphoma at 12 institutio

80 or to chemotherapy (CT) alone, 152 untreated Hodgkin disease patients with clinical stages (CSs) IA,

81 ine demonstrated good activity in refractory Hodgkin disease patients, non-Hodgkin lymphoma, cutaneou

82 The neoplastic cells in classical Hodgkin disease (Reed-Sternberg cells) are of B-lymphoid

83 lls ("L&H" cells) in lymphocyte predominance Hodgkin disease retain the molecular profile of germinal

84 Besides anal cancer and Hodgkin disease, the cohort studies have identified othe

85 of the known risks of pelvic irradiation for Hodgkin disease, the dose associated with UAE is unlikel

86 ts consequences, and from liver diseases and Hodgkin disease, was increased, but for ischemic heart d

87 ogic abnormalities, involving a patient with Hodgkin disease, we identified a larval cestode with a p

88 ients with newly diagnosed known mediastinal Hodgkin disease were evaluated independently by two radi

89 ells in all cases of lymphocyte predominance Hodgkin disease were positive for Fyn, Syk, BLNK, and PL

90 Ten patients had previously been treated for Hodgkin disease, while 12 patients had untreated disease